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ABSTRACT
Background The UK Severe Asthma Registry (UKSAR) 
is the world’s largest national severe asthma registry 
collecting standardised data on referrals to UK specialist 
services. Novel biologic therapies have transformed 
the management of type 2(T2)- high severe asthma but 
have highlighted unmet need in patients with persisting 
symptoms despite suppression of T2- cytokine pathways 
with corticosteroids.
Methods Demographic, clinical and treatments 
characteristics for patients meeting European Respiratory 
Society / American Thoracic Society severe asthma 
criteria were examined for 2225 patients attending 15 
specialist severe asthma centres. We assessed differences 
in biomarker low patients (fractional exhaled nitric oxide 
(FeNO) <25 ppb, blood eosinophils <150/μL) compared 
with a biomarker high population (FeNO ≥25 ppb, blood 
eosinophils ≥150/µL).
Results Age (mean 49.6 (14.3) y), age of asthma 
onset (24.2 (19.1) y) and female predominance (62.4%) 
were consistent with prior severe asthma cohorts. Poor 
symptom control (Asthma Control Questionnaire-6: 
2.9 (1.4)) with high exacerbation rate (4 (IQR: 2, 7)) 
were common despite high- dose treatment (51.7% on 
maintenance oral corticosteroids (mOCS)). 68.9% were 
prescribed biologic therapies including mepolizumab 
(50.3%), benralizumab (26.1%) and omalizumab 
(22.6%). T2- low patients had higher body mass index 
(32.1 vs 30.2, p<0.001), depression/anxiety prevalence 
(12.3% vs 7.6%, p=0.04) and mOCS use (57.9% vs 
42.1%, p<0.001). Many T2- low asthmatics had evidence 
of a historically elevated blood eosinophil count (0.35 
(0.13, 0.60)).
Conclusions The UKSAR describes the characteristics 
of a large cohort of asthmatics referred to UK specialist 
severe asthma services. It offers the prospect of providing 
novel insights across a range of research areas and 
highlights substantial unmet need with poor asthma 
control, impaired lung function and high exacerbation 
rates. T2- high phenotypes predominate with significant 
differences apparent from T2- low patients. However, 
T2- low patients frequently have prior blood eosinophilia 
consistent with possible excessive corticosteroid 
exposure.
INTRODUCTION
Severe asthma has been defined by the European 
Respiratory Society / American Thoracic Society 
(ERS/ATS) as asthma which requires treatment 
with high- dose inhaled corticosteroids (ICS) plus a 
second controller (and/or systemic corticosteroids) 
to prevent it from becoming ‘uncontrolled’ or 
which remains ‘uncontrolled’ despite this therapy.1 
Although some estimates have suggested that severe 
asthma affects approximately 5%–10% of the total 
asthma population,1 2 it is well recognised that many 
patients prescribed high- dose inhaled treatment 
remain poorly controlled because of suboptimal 
adherence to treatment or poor inhaler technique 
despite regular use. Once these two critical aspects 
of asthma care have been addressed the true preva-
lence of patients who remain poorly controlled on 
high- dose inhaled treatment falls to approximately 
3%–4%.3 Exploring the clinical characteristics and 
disease expression in a large well- characterised 
severe asthma cohort is vital to understanding the 
heterogeneity and unmet need in these patients.
The British Thoracic Society (BTS) Difficult 
Asthma Registry was established in 2007 and was 
the first national registry to describe the clinical 
and demographic characteristics in a large patient 
group with well- characterised severe asthma.4 This 
‘real- world’ data describing a population frequently 
underrepresented in clinical trials due to comorbid-
ities or smoking history has been useful in helping 
to define clinical outcomes and health economic 
Key messages
What is the key question?
What are the demographic, clinical and treatment 
characteristics of patients referred to UK specialist 
severe asthma services?
What is the bottom line?
Patients have substantial unmet need despite 
significant background treatment. Clear differences 
exist between T2- low and T2- high phenotypes 
although the majority of the T2- low group 
have evidence of prior T2- high disease, possibly 
reflecting effective suppression of T2 pathways 
with corticosteroids.
Why read on?
This study reports a comprehensive description of 
severe asthma patients in the UK from the largest 
national registry of its kind in the world.
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costs associated with routine clinical care, as well as the signif-
icant morbidity associated with systemic corticosteroids in this 
population.5–14
With our improved understanding of the central role of 
type-2 (T2) inflammation in severe asthma alongside the advent 
of biologic therapies targeting elements of the T2 inflamma-
tory cascade, the original BTS Registry underwent a number of 
important structural changes and was renamed the UK Severe 
Asthma Registry (UKSAR). The data to be collected were 
initially agreed by consensus between UK Expert Physicians 
and in a subsequent Delphi Consensus of International Severe 
Asthma Experts, there was 95% agreement with the UKSAR data 
fields.15 The patient population is well- characterised, with the 
participating centres all being specialist multidisciplinary units 
for asthma care with all patients undergoing systematic assess-
ment prior to inclusion in the registry.
The aims of the current article are to describe the demo-
graphic and clinical characteristics of severe asthma patients 
in the UKSAR, to describe current biologic selection in eligible 
patients and to examine the difference between patients who are 
T2 biomarker- high and T2 biomarker- low at registration.
MATERIALS AND METHODS
Patients in UKSAR are enrolled to the registry after referral to 
Specialist UK Severe Asthma Centres with uncontrolled asthma 
(ie, severe symptoms or frequent exacerbations) at the Global 
Initiative for Asthma (GINA) treatment steps 4 and 5. The UKSAR 
has database ethical approval from the Office of Research Ethics 
Northern Ireland (15/NI/0196) and all patients provide written 
informed consent. All clinical centres in England are part of the 
NHS England Specialist Commissioning Network and operate 
on a ‘hub and spoke’ basis which aims to provide standardised 
multidisciplinary assessment and access to therapies under guid-
ance issued by the National Institute for Clinical and Healthcare 
Excellence. Northern Ireland has a single- centre regional service 
(Belfast) and UKSAR also includes a single specialist regional 
centre in Scotland (online supplemental appendix 1).
Data were collected from November 2016 to February 2020. 
Baseline (at the time of registration) demographic and clinical 
variables are listed in (online supplemental appendix 2, but in 
brief, UKSAR captures 105 core variables classified into nine 
categories: patient demographics, medical history, investigations, 
lung function, allergy testing, Asthma Control Questionnaire, 
EuroQoL Questionnaire, asthma medication, and systematic 
assessment summary and management plan. Follow- up data are 
collected annually. The information recorded at each visit are 
listed in online supplemental appendix 3, however, follow- up 
data are not reported in this manuscript. The number of exac-
erbations was defined as a count of exacerbations requiring 
rescue systemic corticosteroids in the past 12 months. The 
number of hospitalisations and emergency department admis-
sions for asthma was the number in the past 12 months. Asthma 
control was measured using the Asthma Control Question-
naire-6 (ACQ6). In this analysis, all patients were assessed by 
their treating clinician as fulfilling the criteria for severe asthma 
as defined by ERS/ATS Guidelines.1 T2- biomarker low patients 
were defined as fractional exhaled nitric oxide (FeNO) <25 ppb 
and blood eosinophil count <150 cells/µL at registration. These 
cut- points were chosen as phase 3 clinical trials of targeted anti- 
interleukin 5 (IL5) and anti- IL4R biologic therapies have shown 
little benefit below these thresholds in patients with severe 
asthma.16 17 The T2- high comparator cohort was defined when 
both these biomarkers were above these thresholds.
All patients entered into UKSAR have undergone a thorough 
systematic multidisciplinary assessment as previously described 
in UK services.18 19 At this assessment, centres are asked to 
confirm that patients fulfil the ERS/ATS criteria for asthma that 
they have evaluated and optimised adherence to their current 
treatment plan and a management plan including additional 
treatments is registered (see online supplemental). Consecutive 
patients completing this assessment, and consenting to registry 
participation are entered on to the UKSAR.
Statistical analysis
This was a hypothesis generating study with no pre- specified 
hypotheses. Descriptive statistics were calculated for the entire 
cohort and for specific patient subgroups. Mean (with SD) and 
median (with IQR) were presented for continuous variables 
as appropriate. Categorical variables were summarised using 
counts and percentages. Univariate hypothesis tests between 
groups were conducted using t- test, Mann- Whitney U test or χ2 
test. All analyses were conducted using the STATA V.16 software 
package (StataCorp).
RESULTS
Demographic, clinical characteristics and comorbidities
Two thousand two hundred and twenty- five adult patients with 
severe asthma according to ERS/ATS criteria registered between 
November 2016 and February 2020 from 15 centres across the 
UK are included in this data. The mean age at registration was 
49.6 years (14.3) with a mean age at onset of 24.2 years (19.1). 
62.4% were female and 79.1% Caucasian. Self- reported atopic 
disease was recorded in 62.8%; in those reporting a history of 
atopic disease and proceeding to skin prick test or radioaller-
gosorbent (RAST) test, 72% (858 of 1189 patients) were posi-
tive to a perennial environmental allergen. In those reporting 
no atopic disease, 29% (207 of 707) were positive to skin prick 
or RAST- positive suggesting clinical history was of limited 
utility in identifying atopy in this group. Only 3.5% reported 
current smoking whereas 68.3% of patients were never- smokers. 
Patients were poorly controlled with a mean ACQ6 of 2.9 (1.4), 
and a median of 4 (IQR: 2, 7) exacerbations in the previous 
year. Lung function highlighted significant airflow obstruction 
and gas trapping with a FEV1 of 65.3 (21.3) % predicted, a 
FEV1/FVC of 63.4% (17.3%) and a residual volume of 132% 
(44.1%). Reported comorbidities included gastro- oesophageal 
reflux (16.9%), nasal polyposis (16.4%), depression or anxiety 
(8.3%) and eczema (2.9%) (table 1).
Biomarker profile
The median blood eosinophil count at registration was 0.33 
(IQR: 0.16, 0.60) cells×109/L with the median highest historical 
result recorded as 0.62 (IQR: 0.40, 1.00) cells×109/L. Median 
FeNO levels were 39.0 (IQR: 20.0, 75.0) ppb and the median 
total IgE was 181 (IQR: 60, 480) IU/mL (table 2). These levels 
highlight a predominantly T2- high profile in patients entered 
into the UKSAR.
Asthma medication patterns
All patients were on high- dose ICS and long- acting beta agonist 
therapy with a median ICS dose of 2000 (IQR: 1600, 2000) mcg 
BDP equivalent. Of these, 53.5% were additionally on a long- 
acting antimuscarinic antagonist (LAMA), 48.9% on a leukot-
riene receptor antagonist (LTRA) and 27.2% on theophylline. 
There was no evidence of greater airflow obstruction among 
those prescribed a LAMA (FEV1/FVC ratio: 63.2%) compared 
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with those not prescribed one (FEV1/FVC: 64.2%), p=0.111. 
51.7% were on maintenance oral corticosteroids (mOCS) 
with a median daily dose of 10 (IQR: 5, 15) mg prednisolone. 
68.9% were prescribed biologic therapy including mepolizumab 
(50.3%), omalizumab (22.6%), benralizumab (26.1%), resli-
zumab (0.6%) and dupilumab (0.3%) (table 2).
Comparison of biologic prescribed and non-prescribed 
patients with severe asthma
A comparison of the demographic and clinical characteristics 
between patients prescribed biologic therapies and those treated 
with conventional therapies highlighted significant differences 
in several domains. While the age and gender distribution were 
similar, a greater proportion of those prescribed biologics were 
Caucasian (80.6% vs 75.5%; p=0.024). Patients on biologics 
were also more likely to be never- smokers (70.8% vs 62.7%) 
and less likely to be current smokers (2.2% vs 6.4%; p<0.001).
Patients treated with biologics had evidence of more severe 
airflow obstruction (FEV1 64.2% vs 67.7%; p<0.001), greater 
air trapping (residual volume 136.3% vs 120.7%; p<0.001), 
higher registration (0.36 vs 0.30; p<0.001) and historic (0.70 vs 
0.50; p<0.001) blood eosinophil and FeNO levels (41 ppb vs 36 
ppb; p<0.001). Prescription of non- biologic agents also differed 
significantly between patients additionally on biologic therapies. 
Specifically, patients starting on biologics had higher rates of 
mOCS (59.9% vs 33.5%; p<0.001) and LAMA use (54.6% vs 
50.9%; p<0.001), despite lower LTRA use (45.4% vs 56.2%; 
p<0.001) (table 3).
Further differences between biologic and non- biologic treated 
patients were observed with regards to comorbidities, with nasal 
polyposis being more prevalent in biologic patients (18.2% vs 
12.3%; p<0.001), while gastro- oesophageal reflux (13.2% vs 
25.4%; p<0.001) and psychological morbidity (6.2% vs 13.0%; 
p<0.001) being more common in biologic untreated patients 
(table 3).
Clinical characteristics of anti-IgE versus anti-IL5/5R treated 
patients
Analysis of the clinical and phenotypic characteristics of the 
biologic treated patients highlighted a number of significant 
differences between those prescribed the anti- IgE mAb omali-
zumab from those prescribed the anti- IL-5/5R mAbs mepoli-
zumab, reslizumab or benralizumab.
Table 1 Demographic, clinical characteristics and comorbidities*
Number of patients 2225
Age at first assessment 49.6 (14.3)
  18–34 378 (17.0%)
  35–54 979 (44.0%)
  55–79 855 (38.5%)
  80+ 11 (0.5%)
Age at onset of symptoms 24.2 (19.1)
  <12 715 (36.2%)
  12–18 184 (9.3%)
  >18 1076 (54.5%)
Gender
  Female 1389 (62.4%)
  Male 836 (37.6%)
Ethnicity
  Caucasian 1744 (79.1%)
  Non- Caucasian 462 (20.9%)
BMI (kg/m2) 30.8 (7.1)
Smoking status
  Never smoker 1490 (68.3%)
  Ex- smoker 617 (28.3%)
  Current smoker 76 (3.5%)
Atopic disease 1378 (62.8%)
Spinal bone density (T- Score) −0.7 (1.4)
Femoral neck bone density (T- Score) −0.4 (1.1)
FEV1 (% predicted) 65.3 (21.3)
FVC (% predicted) 83.1 (19.7)
FEV1/FVC 63.4 (17.3)
Residual volume (% predicted) 132.0 (44.1)
Total lung capacity (% predicted) 103.9 (18.7)
ACQ6 Score 2.9 (1.4)
Exacerbations requiring rescue steroids in last year 4 (2, 7)
Exacerbations requiring hospital admission in last year 0 (0, 1)
Invasive ventilation (ever) 193 (10.0%)
Eczema 63 (2.9%)
Nasal polyps 356 (16.4%)
Gastro- oesophageal reflux 367 (16.9%)
Depression or anxiety 180 (8.3%)
*Mean (SD), median (IQR) or count (%) as appropriate.
ACQ, Asthma Control Questionnaire; BMI, body mass index.
Table 2 Medication and biomarkers*
Number of patients 2225
Blood eosinophil count (N/109 L) 0.33 (0.16, 0.60)
Highest blood eosinophil count (N/109 L)† 0.62 (0.40, 1.00)
FeNO (ppb) 39.0 (20.0, 75.0)
IgE (IU/mL) 181 (60, 480)
Maintenance oral steroids 1142 (51.7%)
Maintenance oral steroid dose (mg) 10 (5, 15)




Leukotriene receptor antagonist 1048 (48.9%)
Maintenance macrolide 199 (9.3%)
Nebuliser 533 (24.5%)
Prior anti- IgE therapy 251 (11.5%)
Initiate/continue biologic therapy 1524 (68.9%)
Biologic therapy name
  Omalizumab 329 (22.6%)
  Dupilumab 5 (0.3%)
  Mepolizumab 731 (50.3%)
  Benralizumab 380 (26.1%)
  Reslizumab 9 (0.6%)
*Mean (SD), median (IQR) or count (%) as appropriate.
†Highest blood count is the highest recorded in available prior medical records.
FeNO, fractional exhaled nitric oxide; LAMA, long- acting antimuscarinic antagonist; 
SABA, short acting β2- agonist.
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Compared with anti- IL-5/5R treated patients, anti- IgE treated 
patients were younger at first assessment (47.6 vs 50.7 years 
old; p<0.001), had an earlier onset of symptoms (15.2 vs 27.5 
years old; p<0.001), were more likely to be female (66.9% vs 
61.0%; p=0.053) and had a higher reported history of atopic 
disease (86.7% vs 52.6%; p<0.001). In contrast, nasal polyp-
osis was more prevalent in the anti- IL5/5R patients (20.8% vs 
11.1%, p<0.001). Prescribing of other asthma medications 
also differed with prescription of mOCS more prevalent in 
the anti- IL-5/5R patients (65.0% vs 44.6%, p<0.001) and the 
reverse being true for LTRA (43.3% vs 52.4%, p=0.014). In 
keeping with the specific clinical phenotypes these two classes 
of biologic therapies are targeted at, significant differences 
in T2 biomarker levels were observed with a higher registra-
tion (0.40 vs 0.22; p<0.001) and historic (and 0.72 vs 0.50; 
p<0.001) blood eosinophil count in those on anti- IL5/5R ther-
apies and a higher total IgE in those on anti- IgE treatment (294 
vs 143, p<0.001) (table 4). Interestingly although 22.6% of 
biologics patients were prescribed omalizumab, 44.8% of the 
total biologics cohort met published eligibility criteria for this 
therapeutic option.
Comparison of T2-high and T2-low patients
We identified 992 of 2225 (44.6%) patients categorised 
as T2- high and 210 (9.4%) T2- low using our composite 
biomarker definitions. Compared with T2- low patients, those 
in the T2- high group were more likely to be male (39.4% 
vs 32.9%, p=0.076), have an older age of symptom onset 
(25.9 vs 17.1 years old, p<0.001), be a never- smoker (69.7% 
vs 59.1%, p<0.001), have nasal polyposis (19.5% vs 10.8%, 
p=0.006) and have more severe airflow obstruction (FEV1/
FVC 63.6 vs 66.7, p=0.007). In contrast, T2- low patients 
had a higher body mass index (BMI) (32.1 vs 30.2, p<0.001), 
higher prevalence of depression and anxiety (12.3% vs 7.6%, 
p=0.040) and higher rate of current smoking (8.2% vs 2.2%, 
p<0.001). A greater proportion of T2- low patients were 
treated with mOCS (57.9% vs 42.1%, p<0.001) as well as 
theophylline (35.1% vs 23.4%, p=0.001) and more likely to 
have a home nebuliser (35.1% vs 19.6%, p<0.001). A history 
of atopic disease was also more prevalent in the T2- low group 
(71.5% vs 61.8%, p=0.028) although the median IgE was 
higher in the T2- high group (189 vs 155, p=0.007). Impor-
tantly, although the blood eosinophil count on registration 
was used to define T2 status, analysis of the historic blood 
eosinophil counts highlighted a median count of 0.35 (0.13, 
0.60) in the T2- low group (table 5).
Table 3 Biologic population versus non- biologic population*




Age at first assessment 49.1 (14.3) 49.7 (14.3) 0.332
  18–34 118 (17.2%) 257 (16.9%)
  35–54 315 (45.9%) 659 (43.3%)
  55–79 251 (36.5%) 599 (39.4%)
  80+ 3 (0.4%) 7 (0.5%)
Age at onset of symptoms 23.6 (18.9) 24.5 (19.2) 0.321
  <12 230 (37.3%) 481 (35.7%)
  12–18 57 (9.3%) 124 (9.2%)
  >18 329 (53.4%) 742 (55.1%)
Gender 0.964
  Female 428 (62.3%) 951 (62.4%)
  Male 259 (37.7%) 573 (37.6%)
Ethnicity 0.024
  Caucasian 514 (75.5%) 1218 (80.6%)
  Non- Caucasian 167 (24.5%) 293 (19.4%)
BMI (kg/m2) 30.8 (7.4) 30.9 (6.9) 0.747
Smoking status <0.001
  Never smoked 428 (62.7%) 1053 (70.8%)
  Ex- smoker 211 (30.9%) 403 (27.1%)
  Current smoker 44 (6.4%) 32 (2.2%)
Atopic disease 457 (66.7%) 912 (60.9%) <0.001
Spinal bone density (T- Score) −0.7 (1.4) −0.7 (1.4) 0.912
Femoral neck bone density 
(T- Score)
−0.5 (1.1) −0.4 (1.1) 0.446
FEV1 (% predicted) 67.7 (22.0) 64.2 (20.8) 0.001
FVC (% predicted) 83.2 (20.0) 83.0 (19.5) 0.814
FEV1/FVC 65.0 (14.8) 62.7 (18.4) 0.007
Residual volume (% 
predicted)
120.7 (43.7) 136.3 (43.7) <0.001
Total lung capacity (% 
predicted)
100.5 (17.6) 105.0 (19.1) 0.007
ACQ6 Score 3.0 (1.4) 2.9 (1.4) 0.060
Rescue steroids in last year 4 (2, 6) 4 (2, 7) 0.005
Hospital admissions for 
asthma in last year
0 (0, 2) 0 (0, 1) 0.190
Invasive ventilations (ever) 35 (7.2%) 158 (11.0%) <0.001
Eczema 32 (4.9%) 30 (2.0%) <0.001
Nasal polyps 80 (12.3%) 273 (18.2%) <0.001
Gastro- oesophageal reflux 166 (25.4%) 198 (13.2%) <0.001
Depression or anxiety 85 (13.0%) 93 (6.2%) <0.001
Blood eosinophil count 
(N/109 L)
0.30 (0.13, 0.54) 0.36 (0.18, 0.60) <0.001
Highest blood eosinophil 
count (N/109 L)† 0.50 (0.30, 0.82) 0.70 (0.40, 1.10) <0.001
FeNO (ppb) 36.0 (17.0, 69.0) 41.0 (22.0, 76.5) <0.001
IgE (IU/mL) 182 (57, 524) 180 (60, 467) 0.726
Maintenance oral steroids 230 (33.5%) 906 (59.9%) <0.001
Maintenance oral steroid 
dose (mg)
6 (0, 15) 10 (8, 15) <0.001
Inhaled steroid dose (mcg, 
BDP equivalent)
2000 (1600, 2000) 2000 (1600, 2000) 0.056
LAMA 348 (50.9%) 806 (54.6%) <0.001
Continued




Theophylline 177 (25.9%) 414 (27.7%) 0.015
SABA 644 (94.0%) 1434 (95.7%) 0.007
Leukotriene receptor 
antagonist
378 (56.2%) 662 (45.4%) <0.001
Maintenance macrolide 64 (9.6%) 135 (9.3%) 0.077
Nebuliser 154 (22.7%) 377 (25.4%) 0.044
Prior anti- IgE therapy 0 (0.0%) 251 (16.8%) <0.001
*Mean (SD), median (IQR) or count (%) as appropriate.
†Highest blood count is the highest recorded in available prior medical records.
ACQ, Asthma Control Questionnaire; BMI, body mass index; FeNO, fractional exhaled nitric 
oxide; LAMA, long- acting antimuscarinic antagonist; SABA, short acting β2- agonist.
Table 3 Continued
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The UKSAR represents the largest national registry of its kind 
in the world recruiting patients with severe asthma who have 
been systematically evaluated at specialist asthma centres within 
the UK. This includes assessment and confirmation of severity, 
inflammatory phenotype, therapeutic intervention and related 
comorbidities. We report that the majority have evidence of 
T2 inflammation despite high rates of systemic corticosteroid 
use, that T2 low patients have a higher BMI and prevalence 
of anxiety/depression and that a significant unmet need exists 
despite currently available therapies.
In line with the increasing availability of biologic thera-
pies targeting the T2- inflammatory pathway, we report a high 
uptake of biologic therapies in UKSAR, reflecting the fact 
that referrals and registry enrolment are prioritised by centres 
for biologic patients. This is despite eligibility criteria that 
are considered among the most demanding in the world.20–23 
However, we also highlight the sobering finding that over 
half of the UKSAR are on maintenance OCS, continue to have 
a high exacerbation rate averaging four acute OCS courses/
year and remain poorly controlled with an average ACQ6 of 
2.9 at assessment.
The relative proportions of each biologic prescribed in the 
UKSAR reflect the duration of availability of the specific therapy 
at the time of this analysis, the size of the eligible population as 
well as individual prescribing habits of physicians. However, it 
is interesting to note that despite the relatively recent arrival of 
anti- IL5/5R therapies, these make up over 75% of all biologic 
prescribing. This may in part to relate to the relatively high use 
of mOCS to manage severe asthma in the UK and the lack of 
controlled data supporting OCS sparing efficacy with omali-
zumab compared with mepolizumab24 or benralizumab but may 
also relate to the prescribing limitations of body weight and IgE 
levels which limit access to omalizumab.25
In addition, many of the clinical characteristics that differen-
tiate the patients prescribed anti- IgE from anti- IL5/5R in UKSAR 
are in keeping with current understanding of allergic and non- 
allergic asthma phenotypes as well as the results of responder 
analyses conducted following the phase 3 trials of T2 biologics.26 
Specifically, we report that younger atopic patients with an earlier 
disease onset were proportionately more likely to be prescribed 
omalizumab compared with the adult- onset older patients with 
comorbid nasal polyposis who were in much higher numbers in 
the anti- IL-5/5R group.
Our definition of T2- low severe asthma uses cut- points for 
blood eosinophil count and FeNO which have been identified 
in phase 3 clinical trials of biologics targeting anti- IL5/5R and 
anti- IL4R-α respectively, and which have identified little benefit 
of these therapies when the blood eosinophil count is <150 cells/
Table 4 Anti- IgE versus anti- IL5*
Anti- IgE (n=329) Anti- IL5 (n=1120) P value
Age at first assessment 47.6 (14.6) 50.7 (14.1) <0.001
  18–34 71 (21.6%) 167 (14.9%)
  35–54 140 (42.6%) 481 (43.0%)
  55–79 117 (35.6%) 464 (41.5%)
  80+ 1 (0.3%) 6 (0.5%)
Age at onset of symptoms 15.2 (16.0) 27.5 (19.2) <0.001
  <12 168 (60.6%) 279 (27.8%)
  12–18 26 (9.4%) 95 (9.5%)
  >18 83 (30.0%) 630 (62.7%)
Gender 0.053
  Female 220 (66.9%) 683 (61.0%)
  Male 109 (33.1%) 437 (39.0%)
Ethnicity 0.143
  Caucasian 261 (79.3%) 895 (80.8%)
  Non- Caucasian 68 (20.7%) 213 (19.2%)
BMI (kg/m2) 31.3 (6.8) 30.7 (7.0) 0.183
Smoking status 0.757
  Never smoked 233 (72.8%) 763 (69.8%)
  Ex- smoker 81 (25.3%) 307 (28.1%)
  Current smoker 6 (1.9%) 23 (2.1%)
Atopic disease 281 (86.7%) 578 (52.6%) <0.001
Spinal bone density (T- Score) −0.7 (1.4) −0.6 (1.4) 0.593
Femoral neck bone density 
(T- Score)
−0.3 (1.1) −0.5 (1.2) 0.062
FEV1 (% predicted) 63.4 (21.7) 64.9 (20.6) 0.321
FVC (% predicted) 82.4 (18.0) 83.7 (20.2) 0.369
FEV1/FVC 61.8 (14.7) 63.0 (19.8) 0.355
Residual volume (% 
predicted)
138.7 (44.9) 136.8 (43.6) 0.684
Total lung capacity (% 
predicted)
105.6 (17.5) 105.4 (19.6) 0.913
ACQ6 Score 2.8 (1.5) 2.9 (1.4) 0.178
Rescue steroids in last year 4 (2, 6) 4 (3, 7) 0.020
Hospital admissions for 
asthma in last year
0 (0, 1) 0 (0, 1) 0.047
Invasive ventilations (ever) 44 (14.1%) 108 (10.2%) 0.134
Eczema 7 (2.2%) 17 (1.5%) 0.748
Nasal polyps 36 (11.1%) 230 (20.8%) <0.001
Gastro- oesophageal reflux 44 (13.5%) 145 (13.1%) 0.979
Depression or anxiety 21 (6.5%) 65 (5.9%) 0.926
Blood eosinophil count 
(N/109 L)
0.22 (0.10, 0.50) 0.40 (0.20, 0.68) <0.001
Highest blood eosinophil 
count (N/109 L)† 0.50 (0.30, 0.80) 0.72 (0.50, 1.10) <0.001
FeNO (ppb) 31.0 (18.0, 61.0) 44.0 (24.0, 81.0) <0.001
IgE (IU/mL) 294 (151, 485) 143 (47, 407) <0.001
Maintenance oral steroids 145 (44.6%) 723 (65.0%) <0.001
Maintenance oral steroid 
dose (mg)
10 (5, 15) 10 (8, 18) 0.054
Inhaled steroid dose (mcg, 
BDP equivalent)
2000 (1600, 2000) 2000 (1600, 2000) 0.029
LAMA 176 (55.0%) 589 (54.4%) 0.859
Theophylline 102 (31.4%) 289 (26.4%) 0.106
Continued
Anti- IgE (n=329) Anti- IL5 (n=1120) P value
SABA 313 (96.6%) 1054 (95.7%) 0.764
Leukotriene receptor 
antagonist
164 (52.4%) 466 (43.3%) 0.014
Maintenance macrolide 28 (9.0%) 103 (9.6%) 0.713
Nebuliser 89 (27.9%) 267 (24.5%) 0.442
Prior anti- IgE therapy 140 (42.8%) 77 (7.0%) <0.001
*Mean (SD), median (IQR) or count (%) as appropriate.
†Highest blood count is the highest recorded in available prior medical records.
ACQ, Asthma Control Questionnaire; BMI, body mass index; FeNO, fractional exhaled nitric 
oxide; LAMA, long- acting antimuscarinic antagonist; SABA, short acting β2- agonist.
Table 4 Continued
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µL or FeNO is <25 ppb.16 17 Although previous reports of mild- 
moderate asthma using sputum analysis have described an 
approximate 50–50 split between T2- high and T2- low pheno-
types,27 28 it is increasingly recognised that severe asthma is 
predominantly associated with a T2- high phenotype. In keeping 
with this, we found that while the median blood eosinophil 
count at registration in the UKSAR was 0.3 cells×109/L, the 
previous historic (prior to UKSAR registration) median level was 
0.62 cells×109/L with levels greater than 0.4 cells×109/L in 75% 
of the cohort, reflecting prominent blood eosinophilia despite 
substantial background treatment. The median FeNO of 39 ppb 
further supports background T2 inflammatory pathway activa-
tion in this group. Recent data have demonstrated that when 
corticosteroids are down- titrated in a UK severe asthma popu-
lation, T2- biomarkers increase, with the maximal prevalence of 
T2- low severe asthma reported at 5%.29
Indeed, what is perhaps surprising is that such high T2 
biomarker levels were evident despite the very high inhaled 
and systemic steroid utilisation in this cohort and despite 
adherence assessment. Dividing our cohort into T2- high and 
T2- low groups based on the combination of blood eosinophils 
and FeNO at registration highlighted that only a minority of 
patients fulfilled the biomarker definition of T2- low asthma. 
Moreover, analysis of the historic blood eosinophil count in 
the T2- low group revealed a median level consistent with a 
T2- high diagnosis and more than 25% of patients had read-
ings in excess 0.6 cells×109/L. Taken together it highlights 
the difficulties in labelling asthmatics as T2- low given the 
variability of biomarkers such as the blood eosinophil count 
and FeNO in relation to background corticosteroid treat-
ment,29 30 which are known to suppress these biomarkers. 
Consequently, this and any comparison of T2 phenotypes 
using biomarker stratification at a single timepoint, when on 
high- dose corticosteroid treatment is challenging and prone 
to misclassification of patients. It also suggests that cortico-
steroid treatment in these persistently symptomatic patients 
may be elevated beyond a point where there would be any 
additional therapeutic benefit. Consistent with this, we noted 
that 58% of these patients were on maintenance OCS.
In light of the high level of morbidity and mortality which 
we have previously highlighted to be associated with systemic 
steroids31 and the recognition that this therapy is only associated 
with clinical benefit in the presence of T2 inflammation, it would 
Table 5 Comparison of T2- high and T2- low patients*
T2- low (n=210) T2- high (n=992) P value
Age at first assessment 48.1 (15.1) 48.8 (14.3) 0.522
  18–34 47 (22.4%) 173 (17.5%)
  35–54 84 (40.0%) 456 (46.1%)
  55–79 78 (37.1%) 360 (36.4%)
  80+ 1 (0.5%) 1 (0.1%)
Age at onset of symptoms 17.1 (16.6) 25.9 (19.1) <0.001
  <12 96 (53.6%) 282 (31.0%)
  12–18 18 (10.1%) 88 (9.7%)
  >18 65 (36.3%) 540 (59.3%)
Gender 0.076
  Female 141 (67.1%) 601 (60.6%)
  Male 69 (32.9%) 391 (39.4%)
Ethnicity 0.012
  Caucasian 178 (85.2%) 748 (76.4%)
  Non- Caucasian 31 (14.8%) 231 (23.6%)
BMI (kg/m2) 32.1 (7.8) 30.2 (6.7) <0.001
Smoking status <0.001
  Never smoked 123 (59.1%) 688 (69.7%)
  Ex- smoker 68 (32.7%) 277 (28.1%)
  Current smoker 17 (8.2%) 22 (2.2%)
Atopic disease 148 (71.5%) 607 (61.8%) 0.028
Spinal bone density (T- 
Score)
−1.0 (1.4) −0.7 (1.4) 0.010
Femoral neck bone density 
(T- Score)
−0.5 (1.1) −0.4 (1.1) 0.314
FEV1 (% predicted) 66.2 (22.6) 66.5 (20.6) 0.858
FVC (% predicted) 80.6 (19.8) 84.4 (18.7) 0.020
FEV1/FVC 66.7 (14.8) 63.6 (13.7) 0.007
Residual volume (% 
predicted)
122.8 (44.1) 128.1 (44.7) 0.450
Total lung capacity (% 
predicted)
96.2 (22.8) 103.3 (17.7) 0.016
ACQ6 Score 3.1 (1.3) 2.9 (1.4) 0.161
Rescue steroids in last year 4 (1, 7) 4 (2, 8) 0.014
Hospital admissions for 
asthma in last year
0 (0, 2) 0 (0, 1) 0.005
Invasive ventilations (ever) 26 (15.5%) 73 (8.4%) <0.001
Eczema 8 (3.9%) 29 (3.0%) 0.341
Nasal polyps 22 (10.8%) 190 (19.5%) 0.006
Gastro- oesophageal reflux 41 (20.2%) 173 (17.8%) 0.317
Depression or anxiety 25 (12.3%) 74 (7.6%) 0.040
Blood eosinophil count 
(N/109 L)
0.07 (0.01, 0.10) 0.50 (0.30, 0.70) <0.001
Highest blood eosinophil 
count (N/109 L)ϯ 0.35 (0.13, 0.60) 0.76 (0.50, 1.15) <0.001
FeNO (ppb) 14.0 (9.0, 18.0) 60.0 (39.0, 94.0) <0.001
IgE (IU/mL) 155 (34, 437) 189 (67, 509) 0.007
Maintenance oral steroids 121 (57.9%) 415 (42.1%) <0.001
Maintenance oral steroid 
dose (mg)
10 (5, 20) 10 (5, 15) 0.013
Continued
T2- low (n=210) T2- high (n=992) P value
Inhaled steroid dose (mcg, 
BDP equivalent)
2000 (1600, 2000) 2000 (1600, 2000) 0.733
LAMA 116 (56.0%) 527 (54.2%) 0.790
Theophylline 73 (35.1%) 228 (23.4%) 0.001
SABA 196 (94.2%) 937 (95.3%) 0.801
Leukotriene receptor 
antagonist
107 (53.0%) 488 (50.8%) 0.784
Maintenance macrolide 23 (11.4%) 76 (7.9%) 0.248
Nebuliser 73 (35.1%) 189 (19.6%) <0.001
Prior anti- IgE therapy 36 (17.3%) 99 (10.2%) 0.008
*Mean (SD), median (IQR) or count (%) as appropriate.
†Highest blood count is the highest recorded in available prior medical records.
ACQ, Asthma Control Questionnaire; BMI, body mass index; FeNO, fractional 
exhaled nitric oxide; LAMA, long- acting antimuscarinic antagonist; SABA, short 
acting β2- agonist.
Table 5 Continued
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suggest a greater level of OCS stewardship is required in these 
patients. In addition, further work is required to establish the 
mechanism of persistent poor symptom control in these patients 
who lack objective evidence of T2 inflammation as this presum-
ably drives some clinicians to increase corticosteroid treatment 
despite the absence of T2 inflammation. Importantly this will 
require detailed consideration of extrapulmonary factors given 
the elevated BMI and reduced total lung capacity observed in 
this group.32 It is also striking that the rescue corticosteroid 
use in this T2- biomarker low group is identical to the T2- high 
group, given T2- biomarkers have consistently been shown to 
have prognostic value in terms of exacerbation risk. Additionally, 
one would anticipate therapeutic benefit from corticosteroids in 
exacerbations in the T2- high population, but it remains unclear 
if this is also the case in biomarker low patients. As such, under-
standing the mechanism and inflammatory phenotype of exac-
erbation events in T2- biomarker low patients is an important 
future research question. This same issue applies to the residual 
50% of exacerbation events seen in clinical trials of biologic 
therapies targeting T2- pathways and clinical trials are underway 
to try and explore this issue further in patients on mepolizumab 
and benralizumab (NCT03324230 and NCT04102800).
It was also noteworthy that we did not see higher prescription 
rates of LAMA and/or macrolide therapy in the T2 low group 
despite these therapies frequently being discussed as possible 
therapeutic options when a T2 inflammatory signal appears 
absent in severe asthma and particularly given the high symptom 
burden in this population. We cannot identify if these therapies 
were previously tried and withdrawn but ongoing follow- up will 
identify any additional treatment in these patients and if cortico-
steroid treatment is reduced.
Several observations require further investigation. One of 
these is the differences observed in biologic prescribing between 
Caucasian and non- Caucasian patients in the UK. While it is 
possible that variances in access to care, cultural and language 
barriers as well as possible underlying endotype differences may 
all play a role this area, and we have noted different disease by 
ethnicity in UKSAR33 which we are actively exploring further in 
primary care datasets. Additionally, the higher rate of depres-
sion and anxiety seen in the T2- low group as well as the larger 
group of patients not prescribed a biologic therapy deserves 
attention. These patients are frequently on mOCS which have 
well- recognised psychological effects8 34 but our data suggests it 
is not due to a higher rate of exacerbations, hospitalisation or a 
poorer level of asthma control in the non- biologic group. The 
impact of depression and anxiety, and overall quality of life, in 
severe asthma is a major issue that needs further consideration.
The size of our registry cohort now gives us the power to 
understand real- world outcomes of severe asthma patients 
across a common multidisciplinary healthcare system. Annual 
clinical reviews are being entered as registry follow- up entries 
and will allow us to better understand the influence of baseline 
differences on disease trajectory. A further important utility of 
the registry is its potential to highlight the characteristics of UK 
severe asthma to inform the commissioning process and also 
to understand where there might be variation in care between 
centres, and why this might be the case. To facilitate this, we 
have recently reviewed the registry data- metrics, in particular 
reflecting on our current results and in partnership with the NHS 
England Quality Improvement initiative, and have revised the 
data- fields in UKSAR for 2020 onwards (online supplemental 
appendix 2 and 3).
In summary, the UKSAR describes the characteristics of a very 
large cohort of severe asthmatics in routine clinical care across 
the UK with over 1500 patients treated with biologic therapies. 
It highlights current prescribing patterns, the predominance of 
the T2- high clinical phenotype in severe asthma and offers the 
prospect of providing novel insights across a range of research 
areas including real world responses to biologic therapies and 
the natural history of severe asthma.
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Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic 
era 
Appendix 1 - List of UK Severe Networks and Network Leads in UKSAR (2020) 
 
 
Lead Centre & Data Collection Centres Lead Clinician  
Belfast City Hospital Professor Liam Heaney  
 
Royal Brompton and Harefield NHS Trust Professor A Menzies-Gow  
St Georges University Hospital NHS Trust Dr Jane Evans  
 
 
Birmingham Regional Severe Asthma Service 
University Hospitals Birmingham NHS Trust Dr Adel Mansur  
Sandwell & West Birmingham NHS Trust Dr Adeel Sahal  
Royal Wolverhampton NHS Trust Dr Rachid Berair  
Queen Elizabeth Hospital Birmingham Dr Duncan Wilson  
University Hospitals of Derby & Bunton NHS Dr Deepak Subramanian  
The Dudley Group NHS Foundation Trust Dr Martin Doherty  
Worcestershire Acute Hospitals NHS Trust Dr Bethan Barker  
Gloucestershire Hospitals NHS Trust Dr Simon Message  
 
 
South Thames and Kent Severe Asthma Network 
Guy’s & St Thomas’ NHS Trust Dr David Jackson  
 
 
North Central & East London Severe Asthma Service 
Bart’s Health NHS Trust Dr Paul Pfeffer  
Royal Free London NHS Trust Dr Paul Dilworth  
Homerton University Hospital NHS Trust Prof Raja Rajakulasingham  
 
East Midlands Severe Asthma Network 
University Hospitals of Leicester NHS Trust Professor Salman Siddiqui  
Nottingham University Hospital NHS Trust Dr Sherif Gonem  
 
North West Midlands Severe Asthma Service 
University Hospitals of North Midlands NHS Trust Dr Elfatih Idris  
 
Yorkshire Asthma MDT (Yorkshire/Hull/Leeds)  
Sheffield Teaching Hospitals NHS Trust Professor Ian Sabroe  
Hull University Teaching Hospitals NHS Trust Dr Shoaib Faruqi  
The Leeds Teaching Hospitals NHS Trust Dr Ian Clifton  
Chesterfield Royal Hospital Dr Sally Davies  
Doncaster Royal Infirmary Dr Aldrin Adeni & Dr Trevor Rogers  
Wakefield & Dewsbury Hospital Dr James McCreanor & Dr Llinos Jones  
Bradford Royal Infirmary Dr Dinesh Saralaya  
North Lincolnshire & Goole Dr Umesh Bangalore Lakshminarayana  
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York District Hospital Dr Rebecca Thomas  
Airedale Hospital  Dr Su Ann Leong  
Grimsby Hospital Dr Madhav Menon  
Harrogate Hospital Dr Claire Taylor  
Barnsley District General Hospital Dr Hazim Madhi  
Calderdale Hospital Dr Johnnie Walker  
 
East of England Severe Asthma Network 
Cambridge University Hospitals NHS Trust Dr Robin Gore  
 
Wessex Network   
University Hospital Southampton NHS Trust Dr Paddy Dennison  
Portsmouth Hospitals NHS Trust Dr Thomas Browne  
Oxford University Hospitals NHS Trust Professor Ian Pavord  
Churchill Hospital Dr Henry Bettinson  
 
South West Asthma Network   
University Hospitals Plymouth NHS Trust Dr Mitesh Patel  
University Hospitals Bristol NHS Trust Dr James Dodd  
Royal Devon & Exeter NHS Trust Dr Matthew Masoli  
Taunton & Somerset NHS Trust Dr Robert Stone  
  
North West Network  Dr Aashish Vyas 
Wythenshawe Hospital  Dr Rob Niven  
Liverpool Royal Infirmary Dr Hassan Burhan  
Salford Royal  Dr Ronan O’Driscoll  
Countess of Chester Hospital Dr Stephen Scott  
Royal Albert Edward Infirmary Wigan Dr Imran Aziz  
Lancashire Teaching Hospital Dr Aashish Vyas  
North Manchester General Hospital  Dr Nita Seghal  
Wirral University Teaching Hospital Dr John Corless  
Royal Preston Hospital Dr Aashish Vyas  
  
Newcastle Severe Asthma Network  
Newcastle Upon Tyne NHS Trust Dr Simon Doe  
Freeman Hospital Dr Andrew Stanton  
  
NHS Greater Glasgow & Clyde Dr Rekha Chaudhuri 
Gartnavel General Hospital Dr Rekha Chaudhuri  
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Appendix 2: List of Fields collected at baseline (fields in red have been added from June 2020) 
 
Variable Type  Responses 
   
Identifiers 
  
Date First Seen Date 
 
Patient ID Numerical Automatically generated unique UKSAR registration number    
Patient Demographics 
  
Gender Categorical Female; Male 
Age At First Assessment (Years) Numerical 
 
Ethnicity Categorical Caucasian; South East Asian; North East Asian; African; Mixed; Other 
Occupational Cause or Worsening of Asthma Categorical No; Yes 
Height (m) Numerical 
 
Weight (kg) Numerical 
 
BSA (m2) Numerical Calculated dependent field 
BMI (kg/m2) Numerical Calculated dependent field 
Index of Multiple Deprivation Numerical  
Bronchial Thermoplasty Patient Categorical No; Yes 
Research Patient Categorical No; Yes 
Initial Data Complete Categorical No; Yes    
Medical History 
  
Rescue Steroids In Last Year Numerical 
 
Invasive Ventilation Events Ever Numerical 
 
A&E Attendances For Asthma In Last Year Numerical 
 
Hospital Admissions For Asthma In Last Year Numerical 
 
Age at Onset of Symptoms (Years) Numerical 
 
Smoking Status Categorical Never smoked; Ex-smoker; Current smoker 
Pack Years Numerical 
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Years Since Last Smoked Numerical 
 
Nasal Polyps Categorical No; Yes 
Atopic Disease Categorical No; Yes 
Atopic Disease Description Free-text 
 
Current Atopic Eczema Categorical No; Yes 
Other Comorbidity Categorical No; Cardiac disease; Other 
Comorbidity Description Free-text 
 
   
Investigations 
  
Blood Eosinophil Count (N/109L) Numerical 
 
Highest Blood Eosinophil Count [in available 
medical records] (N/109L)  
Numerical 
 
Date Highest Eosinophil Count Date 
 
IgE (IU/mL) Numerical 
 
Prior Highest Sputum Eosinophils (%) Numerical 
 
CT Scan Categorical Not done; Normal; Abnormal 
Abnormal CT Scan Details Free-text 
 
Date Of Bone Densitometry Date 
 
Spinal Bone Density (T-Score) Numerical 
 
Femoral Neck Bone Density (T-Score) Numerical 
 
Additional Clinical Tests Free-text 
 
   
Lung Function 
  
FEV1 (L) Numerical 
 
Predicted FEV1 (L) Numerical Calculated dependent field 
FEV1 (% Predicted) Numerical Calculated dependent field 
Post-BD FEV1 (L) Numerical 
 
Post -BD FEV1 (% Predicted) Numerical Calculated dependent field 
FVC (L) Numerical 
 
Predicted FVC  (L) Numerical Calculated dependent field 
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FVC (% Predicted) Numerical Calculated dependent field 
Post-BD FVC (L) Numerical 
 
Post-BD FVC (% Predicted) Numerical Calculated dependent field 
FEV1/FVC  Numerical Calculated dependent field 
Post-BD FEV1/FVC  Numerical Calculated dependent field 
Residual Volume (% Predicted) Numerical 
 
Total Lung Capacity (% Predicted) Numerical 
 
KCO (% Predicted) Numerical 
 
PC20 Methacholine / Histamine (mg/mL) Numerical 
 
Date of PC20 Methacholine / Histamine Date 
 
FeNO (ppb) Numerical 
 
FeNO Date Date 
 
   
Allergen Testing 
  
Environmental Allergen Test Categorical No; RAST; SPT 
RAST Positive Categorical No; Yes 
SPT Positive Categorical No; Yes 
Positive to Perennial Allergen Categorical No; Yes 
Perennial Allergen Details Free-text 
 
   
Asthma Control Questionnaire 
  
ACQ1 Woken at Night Categorical Never; Hardly ever; A few times; Several times; Many times; A great many times; Unable 
to sleep because of asthma 
ACQ2 Symptoms in Morning Categorical No symptoms; Very mild symptoms; Mild symptoms; Moderate symptoms; Quite severe 
symptoms; Severe symptoms; Very severe symptoms 
ACQ3 Limited in Activities Categorical Not limited at all; Very slightly limited; Slightly limited; Moderately limited; Very limited; 
Extremely limited; Totally limited 
ACQ4 Shortness of Breath Categorical None; A very little; A little; A moderate amount; Quite a lot; A great deal; A very great 
deal 
ACQ5 Wheezing Categorical Never; Hardly any of the time; A little of the time; A moderate amount of the time; A lot 
of the time; Most of the time; All of the time 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax
 doi: 10.1136/thoraxjnl-2020-215168–8.:10 2020;Thorax, et al. Jackson DJ
ACQ6 Puffs of SABA Categorical None; 1 - 2 puffs/inhalations most days; 3 - 4 puffs/inhalations most days; 5 - 8 
puffs/inhalations most days; 9 - 12 puffs/inhalations most days; 13 - 16 puffs/inhalations 
most days; More then 16 puffs/inhalations most days 
ACQ7 FEV1 Categorical > 95% predicted; 95 - 90%; 89 - 80%; 79 - 70%; 69 - 60%; 59 - 50%; < 50% 
ACQ6 Score Numerical Calculated dependent field 
ACQ7 Score Numerical Calculated dependent field    
EuroQoL Questionnaire 
  
EuroQoL Mobility Categorical I have no problems in walking about; I have slight problems in walking about; I have 
moderate problems in walking about; I have severe problems in walking about; I am 
unable to walk about 
EuroQoL Self-care Categorical I have no problems washing or dressing myself; I have slight problems washing or 
dressing myself; I have moderate problems washing or dressing myself; I have severe 
problems washing or dressing myself; I am unable to wash or dress myself 
EuroQoL Usual Activities Categorical I have no problems doing my usual activities; I have slight problems doing my usual 
activities; I have moderate problems doing my usual activities; I have severe problems 
doing my usual activities; I am unable to do my usual activities 
EuroQoL Pain / Discomfort Categorical I have no pain or discomfort; I have slight pain or discomfort; I have moderate pain or 
discomfort; I have severe pain or discomfort; I have extreme pain or discomfort 
EuroQoL Anxiety / Depression Categorical I am not anxious or depressed; I am slightly anxious or depressed; I am moderately 
anxious or depressed; I am severely anxious or depressed; I am extremely anxious or 
depressed 
EuroQoL Health Scale Numerical 
 
   
Mini-AQLQ Questionnaire   
Feel SHORT OF BREATH as a result of your 
asthma 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Feel bothered by or have to AVOID DUST in 
the environment 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Feel FRUSTRATED as a result of your asthma Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
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Feel bothered by COUGHING Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Feel AFRAID OF NOT HAVING YOUR 
ASTHMA MEDICATION AVAILABLE 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Experience a feeling of CHEST TIGHTNESS or 
CHEST HEAVINESS 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Feel bothered by or have to AVOID 
CIGARETTE SMOKE in the environment 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Have DIFFICULTY GETTING A GOOD NIGHT’S 
SLEEP as a result of your asthma 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Feel CONCERNED ABOUT HAVING ASTHMA Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Experience a WHEEZE in your chest Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
Feel bothered by or have to AVOID going 
outside because of WEATHER OR AIR 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the Time; A Little of 
the Time; Hardly Any of the Time; None of the Time 
STRENUOUS ACTIVITIES (such as hurrying, 
exercising, running up stairs, sports) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; Some 
Limitation; A Little Limitation; Not at all Limited 
MODERATE ACTIVITIES (such as walking, 
housework, gardening, shopping, climbing 
stairs) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; Some 
Limitation; A Little Limitation; Not at all Limited 
SOCIAL ACTIVITIES (such as talking, playing 
with pets/children, visiting 
friends/relatives) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; Some 
Limitation; A Little Limitation; Not at all Limited 
WORK-RELATED ACTIVITIES (tasks you have 
do to at work) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; Some 
Limitation; A Little Limitation; Not at all Limited    
Asthma Medication 
  
Maintenance OCS Categorical No; Yes 
Maintenance OCS (mg) Numerical 
 
ICS Categorical No; Yes 
ICS Dose (BDP equivalent/ug) Numerical 
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Steroid Sparing Medication Categorical No; Yes 
Steroid Sparing Medication Name Free-text 
 
Prior Biologic Therapy Categorical No; Yes 
Theophylline Categorical No; Yes 
Theophylline Level (mg/L) Numerical 
 
SABA Categorical No; Yes 
LABA Categorical No; Yes 
LABA Name Free-text 
 
LAMA Categorical No; Yes 
LAMA Name Free-text 
 
Leukotriene Receptor Antagonists Categorical No; Yes 
Maintenance Macrolides Categorical No; Yes 
Nebuliser Categorical No; Yes 
Evidence Of Poor Adherence Categorical No; Prescription records; Objective measures; Clinical impression 
% Expected ICS Prescriptions Filled Numerical 
 
Prednisolone Level Measured Categorical No; Yes (2-4 hours); Yes (>4 hours) 
Prednisolone Level (ng/L) Numerical 
 
FeNO Suppression Categorical Not done; Negative; Positive    
Systematic Assessment and Management Plan 
 
ERS/ATS Severe Asthma Categorical No; Yes; Currently being assessed 
Other Factors Contributing To Symptoms Free-text 
 
Patient Is Adherent With Treatment Categorical No; Yes 
Management Plan Categorical Discharge to local service; Optimisation of current treatment; Biologic therapy; Bronchial 
thermoplasty; Maintenance oral corticosteroids; Steroid sparing agent; Enter into clinical 
trial; Adherence intervention; Other 
Biologic Therapy Details Free-text 
 
Steroid Sparing Details Free-text 
 
Trial Details Free-text 
 
Other Management Plan Free-text 
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Appendix 3: List of Fields collected at follow-up (fields in red have been added from June 2020) 
Variable Type Responses 
   
Identifiers 
  
Date Seen Date 
 
Patient ID Numerical Automatically generated unique UKSAR registration number 
   
Summary 
  
Clinical Summary Free-text 
 
Maintenance OCS Categorical No; Yes 
Maintenance OCS (mg) Numerical 
 
Biologic / SSa  Categorical No; Biologic; Steroid sparing agent 
Biologic Therapy Details Free-text 
 
Biologic / SSa Stopped or Changed Categorical No; Yes 
Reason Biologic / SSa Stopped or Changed Categorical Failed clinical response; Other reason 
Other Reason Biologic / SSa Stopped or Changed Free-text 
 
Maintenance Macrolides Categorical No; Yes 
Rescue Steroids In Last Year Numerical 
 
A&E Attendances For Asthma In Last Year Numerical 
 
Hospital Admissions For Asthma In Last Year Numerical 
 
Height (m) Numerical 
 
Weight (kg) Numerical 
 
Fat Free Mass (%) Numerical 
 
BMI (kg/m2) Numerical Calculated dependent field 
BSA (m2) Numerical Calculated dependent field 
ERS/ATS Severe Asthma Categorical No; Yes 
Serious Medical Event Since Last Entry Categorical None; Anaphylaxis; Severe infection; Malignancy; MI / CVA; Pregnancy; 
Other 
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Severe Infection Details Free-text 
 
Malignancy Details Free-text 
 
Pregnancy Details Categorical Not on Biologic; On Biologic with-held during Pregnancy; On Biologic 
continued during Pregnancy 
Other Serious Medical Event Details Free-text  
Further Details Free-text 
 
Patient Status Categorical Actively managed; Discharged; Lost to follow up; Died; Transferred to 
other centre    
Spirometry 
  
Predicted FEV1 (L) Numerical Calculated dependent field 
Pre-BD FEV1 (L) Numerical 
 
Pre-BD FEV1 (% Predicted) Numerical 
 
Post-BD FEV1 (L) Numerical 
 
Post -BD FEV1 (% Predicted) Numerical 
 
Predicted FVC  (L) Numerical Calculated dependent field 
Pre-BD FVC (L) Numerical 
 
Pre-BD FVC (% Predicted) Numerical 
 
Post-BD FVC (L) Numerical 
 
Post-BD FVC (% Predicted) Numerical 
 
Pre-BD FEV1/FVC  Numerical 
 
Post-BD FEV1/FVC  Numerical 
 
FeNO (ppb) Numerical 
 
Blood Eosinophil Count (N/109L) Numerical 
 
   
Bone Density 
  
Date Of Bone Densitometry Date 
 
Spinal Bone Density (T-Score) Numerical 
 
Femoral Neck Bone Density (T-Score) Numerical 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax
 doi: 10.1136/thoraxjnl-2020-215168–8.:10 2020;Thorax, et al. Jackson DJ
   
Asthma Control Questionnaire 
  
ACQ1 Woken at Night Categorical Never; Hardly ever; A few times; Several times; Many times; A great 
many times; Unable to sleep because of asthma 
ACQ2 Symptoms in Morning Categorical No symptoms; Very mild symptoms; Mild symptoms; Moderate 
symptoms; Quite severe symptoms; Severe symptoms; Very severe 
symptoms 
ACQ3 Limited in Activities Categorical Not limited at all; Very slightly limited; Slightly limited; Moderately 
limited; Very limited; Extremely limited; Totally limited 
ACQ4 Shortness of Breath Categorical None; A very little; A little; A moderate amount; Quite a lot; A great deal; 
A very great deal 
ACQ5 Wheezing Categorical Never; Hardly any of the time; A little of the time; A moderate amount of 
the time; A lot of the time; Most of the time; All of the time 
ACQ6 Puffs of SABA Categorical None; 1 - 2 puffs/inhalations most days; 3 - 4 puffs/inhalations most 
days; 5 - 8 puffs/inhalations most days; 9 - 12 puffs/inhalations most 
days; 13 - 16 puffs/inhalations most days; More then 16 puffs/inhalations 
most days 
ACQ7 FEV1 Categorical > 95% predicted; 95 - 90%; 89 - 80%; 79 - 70%; 69 - 60%; 59 - 50%; < 50% 
ACQ6 Score Numerical Calculated dependent field 
ACQ7 Score Numerical Calculated dependent field 
   
EuroQoL Questionnaire 
  
EuroQoL Mobility Categorical I have no problems in walking about; I have slight problems in walking 
about; I have moderate problems in walking about; I have severe 
problems in walking about; I am unable to walk about 
EuroQoL Self-care Categorical I have no problems washing or dressing myself; I have slight problems 
washing or dressing myself; I have moderate problems washing or 
dressing myself; I have severe problems washing or dressing myself; I am 
unable to wash or dress myself 
EuroQoL Usual Activities Categorical I have no problems doing my usual activities; I have slight problems doing 
my usual activities; I have moderate problems doing my usual activities; I 
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have severe problems doing my usual activities; I am unable to do my 
usual activities 
EuroQoL Pain / Discomfort Categorical I have no pain or discomfort; I have slight pain or discomfort; I have 
moderate pain or discomfort; I have severe pain or discomfort; I have 
extreme pain or discomfort 
EuroQoL Anxiety / Depression Categorical I am not anxious or depressed; I am slightly anxious or depressed; I am 
moderately anxious or depressed; I am severely anxious or depressed; I 
am extremely anxious or depressed 
EuroQoL Health Scale Numerical 
 
   
Mini-AQLQ Questionnaire   
Feel SHORT OF BREATH as a result of your 
asthma 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Feel bothered by or have to AVOID DUST in 
the environment 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Feel FRUSTRATED as a result of your asthma Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Feel bothered by COUGHING Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Feel AFRAID OF NOT HAVING YOUR 
ASTHMA MEDICATION AVAILABLE 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Experience a feeling of CHEST TIGHTNESS or 
CHEST HEAVINESS 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Feel bothered by or have to AVOID 
CIGARETTE SMOKE in the environment 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Have DIFFICULTY GETTING A GOOD NIGHT’S 
SLEEP as a result of your asthma 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Feel CONCERNED ABOUT HAVING ASTHMA Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
Experience a WHEEZE in your chest Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
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Feel bothered by or have to AVOID going 
outside because of WEATHER OR AIR 
Categorical All of the Time; Most of the Time; A Good Bit of the Time; Some of the 
Time; A Little of the Time; Hardly Any of the Time; None of the Time 
STRENUOUS ACTIVITIES (such as hurrying, 
exercising, running up stairs, sports) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; 
Some Limitation; A Little Limitation; Not at all Limited 
MODERATE ACTIVITIES (such as walking, 
housework, gardening, shopping, climbing 
stairs) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; 
Some Limitation; A Little Limitation; Not at all Limited 
SOCIAL ACTIVITIES (such as talking, playing 
with pets/children, visiting 
friends/relatives) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; 
Some Limitation; A Little Limitation; Not at all Limited 
WORK-RELATED ACTIVITIES (tasks you have 
do to at work) 
Categorical Totally Limited; Extremely Limited; Very Limited; Moderate Limitation; 
Some Limitation; A Little Limitation; Not at all Limited 
   
a Steroid sparing medication 
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